Fundraising Fox
🦊/Companies
Sign in

Ossianix

1 known investors

Find your way into Ossianix

Ossianix develops TXP1, a brain-selective shuttle based on a deimmunised VNAR antibody scaffold that targets TfR1 to carry therapeutic payloads across the blood-brain barrier. The company focuses on improving delivery of central nervous system therapeutics to the brain.

BiotechDeep TechHealthtech

Founders & leadership

FS
Frank S WalshCEO (Founder)
JLJ Lynn Rutkowski
J Lynn RutkowskiinCSO (Founder)
SMSteve Moore
Steve MooreinCOO
PSPawel Stocki
Pawel StockiinVP Research

Investors · 1

BioAdvanceConshohocken · $500K – $1.5M

In the news

Ossianix Receives US$800,000 MS Society Funding | Stevenage Bioscience Catalyststevenagecatalyst.com · Jul 2026Ossianix Receives Grant from The Michael J. Fox Foundation | BioAdvance Capitalbioadvance.com · Jan 2025Ossianix Receives Grant from The Michael J. Fox Foundation to Advance TXP1 Brain Shuttle for Delivering TrkB Agonist Antibody in Parkinson’s Disease Therapyossianix.co.uk · Jan 2025Ossianix Announces Lundbeck Investmentossianix.co.uk · Jan 2012

Frequently asked questions

What does Ossianix do?
Ossianix develops TXP1, a brain-selective shuttle based on a deimmunised VNAR antibody scaffold that targets TfR1 to carry therapeutic payloads across the blood-brain barrier. The company focuses on improving delivery of central nervous system therapeutics to the brain.
Who founded Ossianix?
Ossianix was founded by Frank S Walsh, J Lynn Rutkowski.
Who are Ossianix's investors?
Ossianix's investors include BioAdvance.